Roche is planning to file its investigational cancer drug entrectinib following positive results from early and mid-stage trials with patients with ROS1-positive non-small cell lung cancer (NSCLC).
Read More
Pfizer’s Xalkori has been turned away by the National Institute for Health and Care Excellence to treat ROS1-positive advanced non-small cell lung cancer.
Read More
Pfizer has presented Phase II data showing that its next-generation tyrosine kinase inhibitor lorlatinib exhibited “clinically meaningful activity” against lung tumours and brain metastases.
Read More
The European Commission has widened the scope of Pfizer’s Xalkori to include the treatment of adults with ROS1-positive advanced non-small-cell lung cancer.
Read More
